参考来源:‘GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis’,新闻发布。GSK plc;2022年7月27日发布。 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,仅供医护人员内...
Benlysta能够减少导致狼疮患者病情加重的异常B淋巴细胞的数量,这些异常的B淋巴细胞会导致免疫系统产生细胞错误攻击血管和自身其他健康组织,从而引起狼疮和其他免疫系统疾病。 原文出处:GSK receives CHMP positive opinion recommending approval of ...
BENLYSTA is the first and only FDA-approved treatment for both lupus and lupus nephritis. It’s available for adults in 2 administration options—subcutaneous (SC) injectionorintravenous (IV) infusion. For children ages 5 and above with active lupus or lupus nephritis, BENLYSTA is available as ...
Benlysta能够减少导致狼疮患者病情加重的异常B淋巴细胞的数量,这些异常的B淋巴细胞会导致免疫系统产生细胞错误攻击血管和自身其他健康组织,从而引起狼疮和其他免疫系统疾病。 原文出处:GSK receives CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis 本文来源自生物谷,更...
Benlysta能够减少导致狼疮患者病情加重的异常B淋巴细胞的数量,这些异常的B淋巴细胞会导致免疫系统产生细胞错误攻击血管和自身其他健康组织,从而引起狼疮和其他免疫系统疾病。 原文出处:GSK receives CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis...
参考来源: https://www.empr.com/home/news/benlysta-approval-expanded-to-include-pediatric-lupus-nephritis/ haoeyou.com/nafenmixitongjibing/20220801/7182.html 「文中图片来源Pixabay,均已获版权方授权」
BENLYSTA is a prescription medicine used to treat people with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (lupus-related kidney inflammation) who are receiving other lupus medicines. It's unknown if BENLYSTA is safe/effective in children under 5 years when given in...
Benlysta (belimumab) gained FDA approval on March 9, 2011. There is no Benlysta generic or biosimilar. Benlysta uses Benlysta (belimumab) is used to treat adults and children aged 5 years and older (weighing at least 15 kg) with active systemic lupus erythematosus (SLE) when used with standa...
2022年07年27日,GSK plc 宣布,美国食品和药物管理局 (FDA) 已批准Benlysta (belimumab) 用于治疗正在接受标准治疗的5至17岁患有活动性狼疮肾炎 (LN) 的儿童。 狼疮性肾炎是由狼疮引起的严重肾脏炎症,可导致终末期肾脏疾病,需要透析或肾移植。该批准扩大了美国目前的适应症,包括狼疮和活性 LN,用于儿科患者人群的...
"We are delighted with today's decision. Lupus can impact the lives of patients in many different ways with varied and often unpredictable symptoms. Since it launched in its IV form, thousands of patients worldwide have received treatment with ...